Alterome Taps IPO Veteran Johanna Mylet to Steer its KRAS Ambitions

SAN DIEGO, CA – September 08, 2026 – In a move that speaks volumes about its future ambitions, clinical-stage biopharmaceutical company Alterome Therapeutics has appointed Johanna Mylet as its new Chief Financial Officer. While C-suite announcements are routine, this one carries particular weight. Mylet is not just any finance executive; she is the architect who helped steer Poseida Therapeutics from its early days through a successful IPO and its eventual $1.5 billion acquisition by Roche. Her arrival at Alterome signals a clear intent to prepare the company for its next major financial and strategic evolution as it advances a promising pipeline in the fiercely competitive oncology market.

For a company like Alterome, which is navigating the capital-intensive world of clinical trials, bringing on a CFO with Mylet’s specific skill set is a significant strategic advantage. As CEO Jung E. Choi noted in the announcement, her “proven track record of financial stewardship, coupled with her demonstrated ability to finance and scale a biotech company from formation through an initial public offering and into advanced clinical development, makes her an ideal addition to our leadership team.” This isn't just corporate praise; it’s a direct acknowledgment of the playbook Alterome hopes to execute.

A Financial Architect for a Critical Inflection Point

Johanna Mylet’s resume reads like a blueprint for biotech value creation. During her tenure at Poseida, which began in 2015, she was instrumental in its financial maturation. She oversaw a complex array of financing activities—including private rounds, a $224 million IPO in 2020, follow-on offerings, and debt financing—that collectively raised over $500 million. Perhaps more impressively, she helped establish strategic collaborations with industry giants like Roche, Astellas, and Takeda, securing more than $500 million in non-dilutive capital. This dual expertise in tapping both public markets and strategic partners is a rare and coveted combination.

This experience is precisely what Alterome needs as it approaches what Mylet herself calls an "exciting inflection point." The company has already built a solid financial foundation, having raised over $231 million in venture capital, including a substantial $132 million Series B round in April 2024 led by Goldman Sachs Alternatives. This round brought in a syndicate of top-tier investors, signaling strong institutional confidence. However, late-stage clinical development and potential commercialization require a different order of financial magnitude.

Mylet’s appointment is a proactive measure to prepare for these future capital demands. Her experience in navigating the intricate process of an IPO provides Alterome with invaluable institutional knowledge, de-risking a potential public debut for investors. Furthermore, her success in forging major bio-pharma partnerships suggests she has the acumen to structure deals that can fund development without excessively diluting existing shareholders—a critical balance for any emerging biotech. Her role will be to ensure the company has the financial strategy and resources to, as she stated, "fully realize the potential of our pipeline."

Powering a Promising, Crowded Pipeline

The pipeline Mylet is now tasked with funding is aimed squarely at one of oncology’s most challenging and lucrative targets: the KRAS oncogene. For decades, KRAS was considered "undruggable," but recent breakthroughs have ignited a highly competitive race to develop effective therapies. This market is projected to explode from around $500 million in 2023 to nearly $8 billion by 2034, and Alterome is positioning itself to capture a significant piece of it.

The company’s lead candidate, ALTA3263, is a first-in-class, oral KRAS-selective, pan-mutant inhibitor. This is a key differentiator. While the first approved KRAS drugs, such as sotorasib and adagrasib, target a specific mutation (G12C), ALTA3263 is designed to shut down KRAS activity regardless of the specific mutation type. This "pan-mutant" approach could dramatically expand the addressable patient population across a range of solid tumors, including colorectal, pancreatic, and non-small cell lung cancers. Furthermore, the drug is designed to inhibit KRAS in both its active "ON" and inactive "OFF" states, a mechanism intended to provide more durable and tolerable responses. The first patient in the Phase 1 study for ALTA3263 was dosed in March 2025, and the industry is keenly awaiting initial data.

Alterome’s innovative approach doesn't stop there. Its pipeline also includes ALTA2618 (Tanerasertib), a first-in-class inhibitor of the AKT1 E17K mutation, a driver in certain breast and endometrial cancers. This dual focus demonstrates a broader platform capability, built upon the company's proprietary "Kraken platform," which uses a structure-guided machine learning approach to design highly selective small molecules. This technological engine is what underpins the company's potential for long-term value creation.

Reading the Executive Tea Leaves

The move of a high-profile executive from a company that has successfully exited to a clinical-stage venture is always a telling indicator. It suggests that seasoned leaders see an opportunity for significant growth and impact. In a market where experienced life sciences CFOs are in incredibly high demand, Mylet’s decision to join Alterome is a powerful endorsement of its science, leadership, and market potential. Her transition signals confidence not just in the company's assets but also in the management team's ability to execute.

This hire is the latest in a series of strategic leadership appointments. Jung Choi, a precision oncology veteran, took the helm as CEO in April 2025, followed by the appointment of Dr. Leo Faoro as Chief Medical Officer in February 2026 to spearhead clinical development. The addition of Mylet completes a C-suite triangle of scientific, clinical, and financial expertise—a combination that investors and potential partners look for when assessing a company’s viability.

With Mylet managing the financial strategy, Alterome is now better equipped to navigate the path ahead, whether it leads to a public offering, a strategic merger, or a series of high-value partnerships. Her appointment provides a steady hand on the financial tiller, allowing the scientific and clinical teams to focus on the critical task at hand: advancing novel cancer therapies toward the clinic and, ultimately, to the patients who need them. As the company moves closer to key clinical data readouts for its KRAS-targeting program, having a CFO who has already run this race and won gives Alterome a crucial competitive edge.